ESPR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 3.1%, SMA50 -6.04%, SMA200 45.27%). The stock’s 14-day RSI is 49.1 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.8% below its high and over 389.53% above its low. Average 10-day trading volume of 3.62 million shares is below the 3-month average of 5.67 million, indicating normal recent market interest.

Esperion Therapeutics, Inc. has 201.62 million shares outstanding. The public float is 199.76 million shares, elevated short interest at 11.60% of float. This equals 23.13 million shares. The short ratio is 4.77 days. Institutional investors hold 50.9% of the float. Insiders own 0.56%. BIOTECH TARGET N V holds 4.48 million shares, JANNEY DANIEL has 1.48 million shares and Koenig Sheldon L. has 1.47 million shares. Over the past six months, insider transactions show net selling. They sold 105.53 thousand shares across 7 transactions.

Esperion Therapeutics, Inc. generated EPS of -$0.54 over the past year. Five-year average earnings growth is 40.11%. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at $0.27. Next year's EPS is expected at $98.27. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $4.00. The high target offers 371.98% upside. The low target suggests 17.99% downside. The mean target is $11.33. This offers 234.22% upside. Esperion Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -297.65%. The prior quarter beat by -88.24%. Over the last six quarters, Apple has recorded several small beats. These include 118.67% in August 12, 2024.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed at $3.39 USD, gaining $0.07 (2.11%) from the previous close of $3.32. The stock is currently mid-range between its 52-week high and low $0.69 and $4.18. With a market capitalization of about $669.63 million, Esperion Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 5.73 million shares, volume is running light vs its 52-week average. Headquartered in Ann Arbor, MI, Esperion Therapeutics, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Sheldon L. Koenig, the company employs approximately 304 people and listed since June 26, 2013. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.

Esperion Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Esperion Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.65%, with price expected at $3.30 by February 24, 2026, within a range of $3.07 to $3.54 3-Month Outlook: Projected fall of -1.18%, reaching $3.35 by May 08, 2026, with a range of $3.19 to $3.55. 1-Year Outlook: Projected gain of 546.9%, with price at $21.93 by February 10, 2027, within a range of $15.41 to $30.25.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares are down -21.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Esperion Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.32. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $17.52, suggesting 416.81% upside. Our AI forecast model points to short-term weakness (-2.65% over two weeks), a medium-term fall (-1.18% over three months), and a longer-term gain (546.9% over one year), with expected trading ranges indicating moderate volatility.

Esperion Therapeutics, Inc. trades at a P/E ratio of -6.32, slightly below the S&P 500 average, with a price-to-sales ratio of 2.2 and a price-to-book ratio of -1.48 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.15, also above market averages.